Polio vaccine attenuated vaccine strains. In 1958, the National Institutes of Health created a special committee on live polio vaccines. The various vaccines were carefully evaluated for their ability to induce immunity to polio, while retaining a low incidence of neuropathogenicity in monkeys. Large-scale clinical trials performed in the Soviet Union in late 1950s to early 1960s by Mikhail Chumakov and his colleagues demonstrated safety and high efficacy of the vaccine. Based on these results, the Sabin strains were chosen for worldwide distribution. Fifty-seven nucleotide substitutions distinguish the attenuated Sabin 1 strain from its virulent parent (the Mahoney serotype), two nucleotide substitutions
Cold War tensions and the polio vaccine flew to Leningrad in June, 1956. As a result of a cooperation of Sabin and Chumakov in Leningrad, Sabin was able to test his attenuated vaccine when funding in America was declined. While Sabin was working behind the Iron Curtain, the Sabin-Chumakov vaccine was determined to be safe and effective. Cold War tensions caused Western scientists to refuse the reports from the Russians about the effectiveness of the Sabin vaccine. However, mass vaccinations of Sabin's vaccine spread throughout Eastern Europe from 1960–1963. Just as some Soviet virologists did not trust the Western Salk vaccine, Americans had similar reservations about the